the cumulative incidence of relapse was significantly higher in patients with high rather than low ferritin levels (40 vs 19%, P ¼ 0.013) and in patients with high rather than standard risk (49 vs 15%, P ¼ 0.001). The cumulative nonrelapse mortality (NRM) rate was higher in patients with high ferritin levels (32%) than in those with low ferritin levels (17%), although the difference was without statistical Figure 1 ). The 5-year DFS of these groups was 68, 48 and 12%, respectively (Po0.0001). Our data showed that the combination of serum ferritin level and disease risk at transplantation is useful for predicting the outcome of AML and MDS patients following allo-SCT. In a recently published prognostic scoring system, pretransplant serum ferritin level was included as a predictor of survival after all-SCT for acute leukemia or MDS. 6 This report together with our results strongly suggests that measurement of pre-SCT serum ferritin level is useful for predicting the outcome of transplantation in patients with AML or MDS. Our scoring system is simple and may be useful for stratifying patients in clinical studies, although validation should be performed in a large population. 
